Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Etanercept (Enbrel®) is not recommended for use within NHS Wales for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of eight years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. The cost effectiveness data presented was insufficient for AWMSG to recommend the use of etanercept (Enbrel®) in NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | etanercept (Enbrel®) | |
| Formulation | powder and solvent for solution for injection | |
| Reference number | 138 | |
| Indication | Treatment of chronic severe plaque psoriasis in children and adolescents from the age of eight years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies |
|
| Company | Pfizer Ltd | |
| BNF chapter | Skin | |
| Assessment type | Full | |
| Status | Not recommended | |
| Advice number | 0210 | |
| NMG meeting date | 20/01/2010 | |
| AWMSG meeting date | 03/03/2010 | |
| Ratification by Welsh Government | 31/03/2010 | |
| Date of issue | 08/04/2010 | |